25 records found.
Sep 20, 2019
XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
Aug 07, 2019
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 06, 2019
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
Aug 05, 2019
New findings provide definitive management guidelines for patients on direct oral anticoagulants with atrial fibrillation undergoing elective procedures or surgeries
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Jul 08, 2019
XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
Dec 14, 2018
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
Dec 04, 2018
Late-Breaking Clinical Trials Present Clinic-Ready Advances for Non-Malignant Diseases
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Sep 08, 2018
Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing
Aug 26, 2018
Researcher finds new blood clot prevention strategy
Jun 14, 2018
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
May 24, 2018
AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Feb 16, 2018
Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.
Jan 16, 2018
FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin
Dec 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Nov 01, 2017
ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio
Oct 30, 2017
FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms

Pages